Besifloxacin Hydrochloride

CHEMBL1201761 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
430.3 g/mol
LogP
Phase
4

The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.

分子量

430.3000 g/mol

TPSA

86.90 Ų

作用机制

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1

InChI

InChI=1S/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/m1./s1

Molecular Formula

C19H22Cl2FN3O3

HBD / HBA

3 / 7

可旋转键数

3

重原子数

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Besifloxacin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201761. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10224595. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.